Expert Interview
A review of the current standard of care for Diffuse Large B-Cell Lymphoma and the potential of Roche's Polivy
Ticker(s): RHHBYInstitution: University of Colorado
- Assistant Professor within Division of Hematology at University of Colorado; T and NK-cell leukemia/lymphoma program lead
- Research focuses on developing novel management and treatment strategies in aggressive lymphoma subtypes with a focus on mature T and NK cell lymphoproliferative disorders (LPDs), including T-cell lymphomas.
- Principal Investigator of multiple lymphoma clinical trials, specifically focusing on immunotherapy and biomarker driven clinical trials; Aims to translate discoveries grounded in this translational research into early phase clinical trials centering on identifying markers that prognosticate and predict response to specific therapies.
Please describe your background and practice setting
Added By: ben_adminHow many patients with lymphoma do you currently manage? With Large B-Cell lymphoma?
Added By: ben_adminWhat is the current standard of care for these patients?
Added By: ben_adminWhat are you overall thoughts of Roche's POLARIX trial and the potential of Polivy?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
